To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Directive 93/41/EEC of 14 June 1993 on the approximation of national measures relating to the placing on the market of high- technology medicinal products, particularly those derived from biotechnology. The Directive offered two routes for authorising medicinal products, a "centralised" procedure and a procedure of "mutual recognition".
Additional recommended knowledge
According to the Directive, the centralized procedure went through the European European Medicines Evaluation Agency (EMEA). If approved, the Commission issues a decision, valid for 5 years, which is binding on all EU Member States, to authorise the product. The centralized procedure is compulsory for products derived from biotechnology, and optional for other innovative medicinal products.
According to the Directive, the "mutual recognition" procedure involved applications which were made to the Member States selected by the applicant for the marketing authorization and the procedure operates by mutual recognition of national marketing authorisations by the member states of the European Union.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Directive_93/41/EEC". A list of authors is available in Wikipedia.|